DZ3398A1 - Derives pyrazole et leur utilisation comme inhibiteurs des proteines kinases - Google Patents

Derives pyrazole et leur utilisation comme inhibiteurs des proteines kinases

Info

Publication number
DZ3398A1
DZ3398A1 DZ013398A DZ013398A DZ3398A1 DZ 3398 A1 DZ3398 A1 DZ 3398A1 DZ 013398 A DZ013398 A DZ 013398A DZ 013398 A DZ013398 A DZ 013398A DZ 3398 A1 DZ3398 A1 DZ 3398A1
Authority
DZ
Algeria
Prior art keywords
pyrazole derivatives
kinase protein
protein inhibitors
inhibitors
kinase
Prior art date
Application number
DZ013398A
Other languages
English (en)
Inventor
Travis T Wager
Mark Allen Sanner
Christopher Blair Cooper
Christopher John Helal
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DZ3398A1 publication Critical patent/DZ3398A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DZ013398A 2000-08-31 2001-08-24 Derives pyrazole et leur utilisation comme inhibiteurs des proteines kinases DZ3398A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22941500P 2000-08-31 2000-08-31
PCT/IB2001/001540 WO2002018346A1 (fr) 2000-08-31 2001-08-24 Derives pyrazole et leur utilisation en tant qu'inhibiteurs des proteines kinases

Publications (1)

Publication Number Publication Date
DZ3398A1 true DZ3398A1 (fr) 2002-03-07

Family

ID=22861151

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ013398A DZ3398A1 (fr) 2000-08-31 2001-08-24 Derives pyrazole et leur utilisation comme inhibiteurs des proteines kinases

Country Status (38)

Country Link
EP (1) EP1313710A1 (fr)
JP (1) JP2004507526A (fr)
KR (1) KR20030027093A (fr)
CN (1) CN1518543A (fr)
AP (1) AP2001002266A0 (fr)
AR (1) AR035345A1 (fr)
AU (1) AU2001280009A1 (fr)
BG (1) BG107455A (fr)
BR (1) BR0113574A (fr)
CA (1) CA2420363A1 (fr)
CR (1) CR6881A (fr)
CZ (1) CZ2003468A3 (fr)
DO (1) DOP2001000243A (fr)
DZ (1) DZ3398A1 (fr)
EA (1) EA200300205A1 (fr)
EC (1) ECSP034480A (fr)
EE (1) EE200300085A (fr)
GT (1) GT200100179A (fr)
HN (1) HN2001000192A (fr)
HR (1) HRP20030140A2 (fr)
HU (1) HUP0302669A3 (fr)
IL (1) IL154016A0 (fr)
IS (1) IS6687A (fr)
MA (1) MA26946A1 (fr)
MX (1) MXPA03001785A (fr)
NO (1) NO20030958D0 (fr)
NZ (1) NZ523656A (fr)
OA (1) OA12368A (fr)
PA (1) PA8528101A1 (fr)
PE (1) PE20020470A1 (fr)
PL (1) PL360742A1 (fr)
SK (1) SK2002003A3 (fr)
SV (1) SV2002000618A (fr)
TN (1) TNSN01132A1 (fr)
UY (1) UY26909A1 (fr)
WO (1) WO2002018346A1 (fr)
YU (1) YU14703A (fr)
ZA (1) ZA200301064B (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1158985B1 (fr) 1999-01-13 2011-12-28 Bayer HealthCare LLC DIPHENYLE UREES A SUBSTITUTION OMEGA-CARBOXY ARYLE EN TANT QU'INHIBITEURS DE LA KINASE p38
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6638926B2 (en) 2000-09-15 2003-10-28 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CN100436452C (zh) * 2000-12-21 2008-11-26 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡唑化合物
JP2005504093A (ja) * 2001-09-27 2005-02-10 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 内因性テストステロンレベルの増加方法
EP1478358B1 (fr) 2002-02-11 2013-07-03 Bayer HealthCare LLC Tosylate de sorafenib pour le traitement des maladies caractérisées par une angiogénèse anormale
WO2003068229A1 (fr) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation N-oxydes de pyridine, de quinoline, et d'isoquinoline en tant qu'inhibiteurs de kinase
DE60320560T2 (de) * 2002-07-17 2008-12-11 Pfizer Italia S.R.L. Heterobicyclische pyrazolderivate als kinaseinhibitoren
EP1551809A1 (fr) 2002-10-09 2005-07-13 Pfizer Products Inc. Composes pyrazole pour le traitement de maladies neurodegeneratives
WO2004035588A1 (fr) * 2002-10-15 2004-04-29 Smithkline Beecham Corporation Composes de pyradazine utiles comme inhibiteurs de gsk-3
EP1597234B1 (fr) * 2003-02-27 2008-10-08 Smithkline Beecham Corporation Nouveaux composes
CA2526636C (fr) 2003-05-20 2012-10-02 Bayer Pharmaceuticals Corporation Urees de diaryle pour de maladies mediees par le recepteur du facteur de croissance derive des plaquettes
EP1633350B1 (fr) * 2003-06-05 2012-10-03 Elan Pharmaceuticals, Inc. Amino acide amidyle pyrazoles acyles et composes relatifs
PL2256106T3 (pl) 2003-07-22 2015-08-31 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
CL2004001834A1 (es) 2003-07-23 2005-06-03 Bayer Pharmaceuticals Corp Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol
JP2006528661A (ja) * 2003-07-25 2006-12-21 ファイザー・インク アミノピラゾール化合物およびｃｈｋ１阻害剤としての使用
DE602004028150D1 (de) * 2003-11-26 2010-08-26 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
US7244757B2 (en) 2004-04-01 2007-07-17 Pfizer Inc Pyrazole-amine compounds for the treatment of neurodegenerative disorders
US20090227648A1 (en) * 2004-04-21 2009-09-10 Astrazeneca Ab Pyrazole derivatives useful for the treatment of cancer
MXPA06012394A (es) 2004-04-30 2007-01-31 Bayer Pharmaceuticals Corp Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer.
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
WO2006004865A1 (fr) * 2004-06-29 2006-01-12 Rigel Pharmaceuticals, Inc. Composés de quinoléine de substitution et leurs utilisations comme inhibiteurs de la cascade de signalement du récepteur d'immunoglobuline (ige)
US7491720B2 (en) 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
JP2008520713A (ja) 2004-11-17 2008-06-19 ミイカナ セラピューティクス インコーポレイテッド キナーゼ阻害剤
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
SI2383268T1 (sl) 2005-02-04 2016-02-29 Astrazeneca Ab Derivati pirazolilaminopiridina uporabni kot kinazni inhibitorji
WO2006085685A1 (fr) * 2005-02-09 2006-08-17 Takeda Pharmaceutical Company Limited Dérivé de pyrazole
PT1853588E (pt) 2005-02-16 2008-08-25 Astrazeneca Ab Compostos químicos
CA2608009A1 (fr) 2005-05-16 2006-11-23 Astrazeneca Ab Composes chimiques
EP1741708A1 (fr) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Amides heterocycliques substitués contenant un linker cyclique ou insaturé, et leur utilisation comme agent pharmaceutique
EP2275095A3 (fr) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenese par modulation des recepteurs muscariniques
EP2258359A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
KR20140025610A (ko) 2005-09-30 2014-03-04 미카나 테라퓨틱스, 인크. 치환된 피라졸 화합물
EP2377530A3 (fr) 2005-10-21 2012-06-20 Braincells, Inc. Modulation de neurogénèse par inhibition PDE
ES2391783T3 (es) 2005-10-28 2012-11-29 Astrazeneca Ab Derivados de 4-(3-aminopirazol)pirimidina para su uso como agentes inhibidores de las tirosina cinasas en el tratamiento del cáncer
EP2314289A1 (fr) 2005-10-31 2011-04-27 Braincells, Inc. Modulation de la neurogenese dont la médiation est assurée par récepteur gaba
AU2006311830B2 (en) 2005-11-03 2013-03-14 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651813A1 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenese par modulation de l'angiotensine
WO2008047364A2 (fr) * 2006-10-18 2008-04-24 Periness Ltd. Composition pharmaceutique destinée au diagnostic et au traitement de l'hypofertilité masculine
US8642598B2 (en) * 2006-10-21 2014-02-04 Abbvie Inc. Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
WO2008090117A1 (fr) 2007-01-24 2008-07-31 Glaxo Group Limited Nouvelles compositions pharmaceutiques
CN101808994B (zh) 2007-07-17 2013-05-15 普莱希科公司 用于激酶调节的化合物和方法以及其适应症
WO2009017453A1 (fr) * 2007-07-30 2009-02-05 Astrazeneca Ab Nouvelle combinaison thérapeutique d'antipsychotique et d'inhibiteur de gsk3 958
MX2010002772A (es) 2007-09-21 2010-03-31 Array Biopharma Inc Derivados de piridin-2-il-amino-1,2,4-tiadiazol como activadores de glucocinasa para el tratamiento de diabetes mellitus.
WO2009130900A1 (fr) * 2008-04-24 2009-10-29 日本曹達株式会社 Dérivé d’oxime, composé intermédiaire et agent de lutte contre des maladies végétales
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9447089B2 (en) 2009-04-03 2016-09-20 Plexxikon Inc. Compositions and uses thereof
JP2013506691A (ja) * 2009-10-02 2013-02-28 バーテックス ファーマシューティカルズ インコーポレイテッド ホスファチジルイノシトール３−キナーゼのピラゾール阻害薬
UA105813C2 (uk) 2009-11-06 2014-06-25 Плексікон, Інк. Сполуки-інгібітори кіназ та фармацевтична композиція (варіанти)
CA2810954A1 (fr) 2010-09-27 2012-04-05 Abbott Gmbh & Co. Kg Composes heterocycliques et leur utilisation en tant qu'inhibiteurs de la glycogene synthase kinase-3
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
AU2012214762B2 (en) 2011-02-07 2015-08-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
US9790216B2 (en) 2013-08-16 2017-10-17 Merck Patent Gmbh 3-substituted cyclopentylamine derivatives
CN106580986B (zh) * 2016-11-28 2017-09-15 王保亮 一种治疗少弱精子症的药物组合物
US11174263B2 (en) 2018-12-31 2021-11-16 Biomea Fusion, Inc. Inhibitors of menin-MLL interaction
BR112021011578A2 (pt) 2018-12-31 2021-08-31 Biomea Fusion, Llc Inibidores irreversíveis de interação menina-mll
CA3128155C (fr) * 2019-01-31 2023-09-19 Pfizer Inc. Composes 3-carbonylamino-5-cyclopentyl-1h-pyrazole ayant une activite inhibitrice sur cdk2
WO2022135442A1 (fr) * 2020-12-22 2022-06-30 上海拓界生物医药科技有限公司 Inhibiteur de cdk2 et son procédé de préparation
US11932648B2 (en) 2021-06-28 2024-03-19 Blueprint Medicines Corporation CDK2 inhibitors
TW202317564A (zh) * 2021-07-01 2023-05-01 大陸商上海拓界生物醫藥科技有限公司 Cdk2抑制劑及其製備方法和用途
JP2024534014A (ja) 2021-08-20 2024-09-18 バイオメア フュージョン，インコーポレイテッド 癌の処置のための不可逆的メニン－ＭＬＬ阻害剤、Ｎ－［４－［４－（４－モルホリニル）－７Ｈ－ピロロ［２，３－ｄ］ピリミジン－６－イル］フェニル］－４－［［３（Ｒ）－［（１－オキソ－２－プロペン－１－イル）アミノ］－１－ピペリジニル］メチル］－２－ピリジンカルボキサミドの結晶形態
WO2023083201A1 (fr) * 2021-11-09 2023-05-19 上海拓界生物医药科技有限公司 Dérivé d'aminopyrazole, son procédé de préparation et son utilisation
WO2023092088A1 (fr) * 2021-11-19 2023-05-25 Blueprint Medicines Corporation Inhibiteurs de cdk2 et leurs procédés de fabrication et d'utilisation
WO2023239629A1 (fr) * 2022-06-06 2023-12-14 Plexium, Inc. Composés et compositions pharmaceutiques qui dégradent cdk2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2198999A (en) * 1997-12-22 1999-07-12 Bayer Corporation Inhibition of raf kinase using substituted heterocyclic ureas
KR100579792B1 (ko) * 1998-05-13 2006-05-12 동화약품공업주식회사 신규 2,5-피리딘디카복실산 유도체
GB9811427D0 (en) * 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
ES2251395T3 (es) * 1999-07-26 2006-05-01 Banyu Pharmaceutical Co., Ltd. Derivados de biarilureas.
DE60023012T2 (de) * 1999-08-12 2006-07-20 Pharmacia Italia S.P.A. 3(5)-amino-pyrazolderivate, deren herstellungsverfahren und verwendung als krebshemmende mittel
US6387900B1 (en) * 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
AU1047601A (en) * 1999-11-30 2001-06-12 Pfizer Products Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
WO2001079198A1 (fr) * 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles permettant d'inhiber des proteines kinases

Also Published As

Publication number Publication date
ZA200301064B (en) 2004-04-19
HN2001000192A (es) 2001-08-28
IS6687A (is) 2003-01-16
PE20020470A1 (es) 2002-06-18
HUP0302669A2 (hu) 2003-12-29
CR6881A (es) 2004-03-11
HRP20030140A2 (en) 2003-04-30
BG107455A (en) 2003-09-30
MXPA03001785A (es) 2003-06-04
JP2004507526A (ja) 2004-03-11
CZ2003468A3 (cs) 2004-05-12
EP1313710A1 (fr) 2003-05-28
NO20030958L (no) 2003-02-28
AR035345A1 (es) 2004-05-12
ECSP034480A (es) 2003-03-31
WO2002018346A1 (fr) 2002-03-07
HUP0302669A3 (en) 2004-03-29
EA200300205A1 (ru) 2003-06-26
UY26909A1 (es) 2002-03-22
PL360742A1 (en) 2004-09-20
BR0113574A (pt) 2003-07-22
KR20030027093A (ko) 2003-04-03
PA8528101A1 (es) 2002-07-30
IL154016A0 (en) 2003-07-31
AP2001002266A0 (en) 2001-09-30
CN1518543A (zh) 2004-08-04
NO20030958D0 (no) 2003-02-28
SV2002000618A (es) 2002-10-24
DOP2001000243A (es) 2002-10-15
TNSN01132A1 (fr) 2005-11-10
SK2002003A3 (en) 2004-04-06
EE200300085A (et) 2004-12-15
GT200100179A (es) 2002-04-22
AU2001280009A1 (en) 2002-03-13
YU14703A (sh) 2006-05-25
MA26946A1 (fr) 2004-12-20
NZ523656A (en) 2004-11-26
OA12368A (en) 2004-04-13
CA2420363A1 (fr) 2002-03-07

Similar Documents

Publication Publication Date Title
DZ3398A1 (fr) Derives pyrazole et leur utilisation comme inhibiteurs des proteines kinases
ATE318814T1 (de) Kondensierte pyrazol derivate als protein kinase inhibitoren
PT1318997E (pt) Compostos de pirazole uteis como inibidores de proteina-quinase
ATE445613T1 (de) Indolylmaleimidderivative als proteinkinase-c- inhibitoren
FR13C0003I2 (fr) Inhibiteurs cycliques de proteine tyrosine kinase
ATE353890T1 (de) Pyrazolverbindungen als proteinkinasehemmer
AU2728201A (en) 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
NO20023713D0 (no) 2-benzotiazolyl-urea-derivater samt anvendelse derav som proteinkinaseinhibitorer
DE60129794D1 (de) Pyrrol substituierte indolin-2-on protein kinase inhibitoren
EE200200576A (et) Oksasooli derivaadid ja nende kasutamine türosiini kinaasi inhibiitoritena
NO20021820D0 (no) Tyrosinkinaseinhibitorer
AU2001270260A1 (en) 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
AU2002358198A1 (en) Benzimidazole derivatives and their use as kdr protein kinase inhibitors
IL172840A (en) Benzimidazole history and their use as a protein kinase inhibitor